AUGMEDIX INC (AUGX)
US05105P1075 - Common Stock
Overall AUGX gets a fundamental rating of 2 out of 10. We evaluated AUGX against 40 industry peers in the Health Care Technology industry. AUGX has a bad profitability rating. Also its financial health evaluation is rather negative. AUGX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AUGX has reported negative net income.
In the past year AUGX has reported a negative cash flow from operations.
AUGX had negative earnings in each of the past 5 years.
AUGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AUGX's Return On Assets of -28.74% is in line compared to the rest of the industry. AUGX outperforms 53.85% of its industry peers.
AUGX has a Return On Equity (-82.21%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.74% | ||
| ROE | -82.21% | ||
| ROIC | N/A |
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 48.00%, AUGX perfoms like the industry average, outperforming 41.03% of the companies in the same industry.
In the last couple of years the Gross Margin of AUGX has grown nicely.
AUGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
2. Health
2.1 Basic Checks
AUGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AUGX has been increased compared to 1 year ago.
AUGX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AUGX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.90, we must say that AUGX is in the distress zone and has some risk of bankruptcy.
AUGX's Altman-Z score of -1.90 is in line compared to the rest of the industry. AUGX outperforms 41.03% of its industry peers.
A Debt/Equity ratio of 0.66 indicates that AUGX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.66, AUGX is doing worse than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.9 |
ROIC/WACCN/A
WACC10.68%
2.3 Liquidity
A Current Ratio of 2.41 indicates that AUGX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.41, AUGX is in line with its industry, outperforming 58.97% of the companies in the same industry.
A Quick Ratio of 2.41 indicates that AUGX has no problem at all paying its short term obligations.
AUGX has a Quick ratio (2.41) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.41 |
3. Growth
3.1 Past
AUGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.59%, which is quite impressive.
Looking at the last year, AUGX shows a very strong growth in Revenue. The Revenue has grown by 45.04%.
Measured over the past years, AUGX shows a very strong growth in Revenue. The Revenue has been growing by 32.90% on average per year.
EPS 1Y (TTM)31.59%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q40%
Revenue 1Y (TTM)45.04%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Revenue growth Q2Q44.91%
3.2 Future
Based on estimates for the next years, AUGX will show a small growth in Earnings Per Share. The EPS will grow by 7.06% on average per year.
AUGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.70% yearly.
EPS Next Y-17.87%
EPS Next 2Y7.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year36.62%
Revenue Next 2Y37.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AUGX. In the last year negative earnings were reported.
Also next year AUGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.06%
EPS Next 3YN/A
5. Dividend
5.1 Amount
AUGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AUGMEDIX INC
NASDAQ:AUGX (5/16/2024, 3:50:58 PM)
After market: 1.18 -0.05 (-4.07%)1.23
+0.04 (+3.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap59.95M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.74% | ||
| ROE | -82.21% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.41 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)31.59%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-17.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)45.04%
Revenue growth 3Y39.62%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y